2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Bhavana Pothuri, MD, discusses patient-reported outcomes with niraparib in advanced ovarian cancer.
Bhavana Pothuri, MD, professor, Department of Obstetrics and Gynecology, NYU School of Medicine, director of gynecologic oncology clinical trials, NYU Langone Health’s Perlmutter Cancer Center, discusses patient-reported outcomes (PROs) with niraparib (Zejula) in advanced ovarian cancer.
During the 2020 ESMO Virtual Congress, findings from an analysis of the phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial revealed that patients with newly diagnosed advanced ovarian, primary peritoneal, or fallopian tube cancer who derived a complete or partial response to first-line platinum-based chemotherapy and who received niraparib had similar quality of life (QOL) compared with patients who received placebo.
FOSI [Validation of the Functional Assessment of Cancer Therapy-Ovarian Symptom Index] scores were similar in patients who received niraparib versus placebo, Pothuri reports. Moreover, the number of patients who reported lethargy, nausea, vomiting, and abdominal cramps were similar between arms.
As determined by the EORTC-QLQ-C30 questionnaire, QOL was similar between arms, Pothuri says. Additionally, abdominal and gastrointestinal symptoms, as well as other chemotherapy-related adverse effects were similar as determined by the EORTC-QLQ-OV28 instrument.
Finally, the overall QOL of patients was shown to be similar based on the EQ-5D-5L index, concludes Pothuri.